Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 3/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.46 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.45 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19707300 | 0.91 | THRA (0.51) | KAT6ATAS1R3TAS1R1TAS1R2THRA | |
| SCHEMBL27629715 | 0.90 | THRA (0.53) | KAT6ATAS1R3TAS1R1TAS1R2THRA | |
| SCHEMBL13780117 | 0.88 | KAT6A (0.52) | KAT6ATAS1R3TAS1R1TAS1R2GPR139 | |
| SCHEMBL2091938 | 0.85 | KAT6A (0.50) | KAT6ATAS1R3TAS1R1TAS1R2GPR139 | |
| SCHEMBL3142098 | 0.84 | KAT6A (0.49) | KAT6ATAS1R3TAS1R1TAS1R2THRA | |
| SCHEMBL19707956 | 0.83 | PDE4A (0.51) | THRATHRBMRGPRX4KMT2A | |
| SCHEMBL15382733 | 0.83 | KAT6A (0.53) | KAT6ATAS1R3TAS1R1TAS1R2GPR139 | |
| SCHEMBL5541493 | 0.82 | KAT6A (0.48) | KAT6ATAS1R3TAS1R1TAS1R2GPR139 | |
| SCHEMBL23617805 | 0.82 | TAS1R3 (0.53) | KAT6ATAS1R3TAS1R1TAS1R2GPR139 | |
| SCHEMBL29467073 | 0.82 | NPC1 (0.50) | KAT6ATAS1R3TAS1R1TAS1R2GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3307258-B1 | ARYL SULFONOHYDRAZIDES | UNIV MONASH (AU) | 2020-12-16 | — | — | EP | disclosed |
| US-20190134005-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARM INC (US) | 2019-05-09 | — | — | US | disclosed |
| WO-2017214505-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134005-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | UGCG, MAN2B1, GBA1 | KAT6A 845/4885TAS1R3 4234/4885TAS1R1 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.